Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E18.35 EPS (ttm)5.48 Insider Own0.02% Shs Outstand2.77B Perf Week-3.73%
Market Cap278.19B Forward P/E14.63 EPS next Y6.87 Insider Trans-25.89% Shs Float2.77B Perf Month0.15%
Income15.41B PEG3.56 EPS next Q1.65 Inst Own67.40% Short Float1.05% Perf Quarter-0.65%
Sales70.07B P/S3.97 EPS this Y18.50% Inst Trans0.05% Short Ratio3.48 Perf Half Y3.01%
Book/sh25.85 P/B3.89 EPS next Y6.06% ROA11.20% Target Price108.94 Perf Year1.03%
Cash/sh13.48 P/C7.46 EPS next 5Y5.15% ROE21.00% 52W Range81.19 - 105.49 Perf YTD-2.12%
Dividend3.00 P/FCF40.25 EPS past 5Y5.30% ROI18.40% 52W High-4.69% Beta0.63
Dividend %2.98% Quick Ratio2.20 Sales past 5Y3.70% Gross Margin69.30% 52W Low23.83% ATR2.10
Employees126500 Current Ratio2.50 Sales Q/Q-7.40% Oper. Margin25.90% RSI (14)47.94 Volatility1.88% 2.08%
OptionableYes Debt/Eq0.28 EPS Q/Q-27.70% Profit Margin21.00% Rel Volume1.85 Prev Close103.90
ShortableYes LT Debt/Eq0.20 EarningsJan 26 BMO Payout55.80% Avg Volume8.37M Price100.54
Recom2.30 SMA200.83% SMA50-0.83% SMA2002.37% Volume15,511,589 Change-3.23%
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Feb-05-16 10:17PM  [$$] J&J, AbbVie Shares Drop on Potential Drug Competition at The Wall Street Journal
04:13PM  Call Martin Shkreli Whatever You Want, But Not A Pharma CEO at Forbes
04:01PM  The 4 Stocks That Tanked the Dow on Friday at 24/7 Wall St.
01:22PM  [$$] J&J, AbbVie Shares Drop on Potential Drug Competition at The Wall Street Journal
01:19PM  A Checkup On A Big Healthcare ETF
11:55AM  Another Stock Market Meltdown; Nike Leads Dow Down 200 Points
10:53AM  Techs Tumble in Early Trade; Tyson Foods Wings Higher
09:20AM  String of Q4 Earnings Beat Fails to Revive Pharma ETFs
09:01AM  Why Isnt Johnson & Johnson Making More Acquisitions? at Motley Fool
08:02AM  Celltrions Copy of J&Js Remicade Gets FDA Staff Support at Bloomberg
07:00AM  Cheap Exposure to Large-Value Stocks at Morningstar
Feb-04-16 06:16PM  2 Numbers in Merck's 4th-Quarter Report That Have Investors Worried at Motley Fool
03:40PM  Why Achillion Pharmaceuticals Shares Crashed 37% in January at Motley Fool
03:13PM  How To Build A Defensive Portfolio
01:33PM  Lab criticised as slow to act in fatal French drug trial Reuters
12:55PM  [$$] Activist investors: hard drugs at Financial Times
10:41AM  Activist Investors Are Taking Aim at the Largest Healthcare Company on Earth at Motley Fool
09:00AM  Stock Market Today - January U.S. Jobless Claims Up, Stock Futures Down at TheStreet
08:30AM  Seeking Value, Growth and Momentum -- Analyst Notes on Comcast, Coca-Cola, Johnson & Johnson and 3M Accesswire
08:06AM  A Cure for Diabetes Is Moving Closer Toward Reality at Fortune
04:46AM  US company tests possible diabetes cure AAP
12:05AM  Johnson & Johnson, ViaCyte testing possible diabetes cure
Feb-03-16 04:48PM  Johnson & Johnson's 3 Most Profitable Lines of Business (JNJ) at Investopedia
03:21PM  Here's How 10 of the Biggest Stock 'Darlings' Did in January at TheStreet
02:04PM  One Big Threat to Johnson & Johnson's Future at Motley Fool
10:33AM  Michael Kors -- On Its Way to $60?
10:19AM  Will 2016 Be Amgen Inc.'s Best Year Yet? at Motley Fool
09:46AM  [$$] GlaxoSmithKline rules out break up as new drugs boost sales at Financial Times
07:27AM  Pfizer, J&J, Merck evaluating technologies for Zika vaccine
06:40AM  Why Medivation, Inc. Shares Crashed 32% in January at Motley Fool
Feb-02-16 10:48PM  The Biggest Risks of Investing in Johnson & Johnson Stock (JNJ) at Investopedia
03:14PM  Three Blue-Chip Dividend Stocks Poised to Pop in February at TheStreet
03:03PM  The 1 Dividend Stock I Want to Own in 2016 at Motley Fool
02:34PM  The C-Suite Speaks: Business as Usual?
02:00PM  Top Stocks for Retirees at Motley Fool
12:05PM  J&J's Talcum Powder Goes on Trial in Ovarian Cancer Lawsuits at Bloomberg
11:51AM  Jim Cramer Examines 2016's Big Investment Theme at TheStreet
08:07AM  Growth of Abbotts Nutrition Segment Driven by Sales
08:00AM  The Institute of Cancer Research, London Sells a Portion of Its Royalty Entitlement Relating to Sales of Johnson & Johnsons Zytiga® to Dri Capital Managed Fund Business Wire
07:44AM  Forget Merck & Co. Inc.: Here Are 2 Better Dividend Stocks at Motley Fool
01:00AM  [$$] J&J and GSK join Medicxi's European life sciences push at Financial Times
Feb-01-16 04:07PM  Novartiss 2015 Revenues Rise 5% at Constant Currencies
02:12PM  Dividend Aristocrats Part 50: Johnson & Johnson (JNJ) at Insider Monkey
02:03PM  These Drugs Are Actually Moving The Needle For Johnson & Johnson at Motley Fool
01:52PM  Why TransEnterix, Inc. Shares Are Soaring Today at Motley Fool
01:07PM  Can Consumer Healthcare Drive Sanofis Revenue?
12:08PM  [$$] Investor calls for big pharma to slim down grow louder at Financial Times
10:40AM  Monsanto CIO Jim Swanson Leads A Digital Revolution Of The World's Oldest Industry at Forbes
10:18AM  The Single Best Stock to Own Today at Motley Fool
09:41AM  Warm Up With This Low Volatility ETF
09:30AM  The Zacks Analyst Blog Highlights: Caterpillar, McDonald's, 3M, Procter & Gamble and Johnson & Johnson
07:30AM  Trading the path higher in Johnson & Johnson
06:45AM  [$$] Lasting lessons for smug CEOs and somnolent shareholders at Financial Times
Jan-31-16 02:20PM  How to Trade 6 Dow Components on Jim Cramers 'Anointed' List of Stocks at TheStreet
10:38AM  Johnson & Johnson Wants Investors to Ignore Falling Hepatitis C Drug Sales at Motley Fool
Jan-30-16 05:45PM  J&J (JNJ) Beats on 4Q Earnings but Misses on Revenues
12:00PM  Here's Why Johnson & Johnson's Sales Fell Last Year at Motley Fool
08:18AM  What Johnson & Johnson's Restructuring Means at Motley Fool
08:05AM  Becton, Dickinson and Companys 1Q16 Earnings Estimates
06:02AM  3 reasons you shouldn't worry about the stock market in 2016 at USA TODAY
12:01AM  [$$] Solid Payouts in Small-Cap Land at
Jan-29-16 07:01PM  Cramer: It's the Attack of the Killer Quarters!
06:36PM  Cramer: Your shopping list for the next market dip at CNBC
06:25PM  Cramer: Accentuating the positives
04:29PM  The Weeks Top Mutual Funds How Good Were Yours?
04:18PM  Johnson & Johnson's Results Include a Healthy Dose of Asterisks at Motley Fool
01:56PM  ORTHO-CLINICAL DIAGNOSTICS SA -- Moody's downgrades ratings of Ortho-Clinical; CFR to B3 and Unsecured Notes to Caa2 at Moody's
12:16PM  Small Deals to Continue in 2016 for Johnson & Johnson at Motley Fool
11:05AM  Does Trump believe Medicare should negotiate prices? at CNBC
10:02AM  Heres what CEOs said on this weeks earnings calls
Jan-28-16 04:31PM  [$$] Caterpillar warns of another difficult year at Financial Times
03:27PM  Large Johnson & Johnson Shareholder Just Revealed 8 Major Concerns
03:12PM  JNJs 2015 Revenues Rise 1.8% on a Constant Currency Basis
03:12PM  Johnson & Johnson Reports Operational Growth in 4Q15
02:47PM  Reading the US Stock Index Reaction to Oils Latest Rebound
02:18PM  2 Top Stocks to Buy with Dividends Yielding More Than 3% at Motley Fool
01:28PM  Here's Why Transenterix (TRXC) Stock Is Spiking Today at TheStreet
12:43PM  4 Reasons Why Johnson & Johnson Exploded Higher Following Its Q4 Earnings Release at Motley Fool
11:17AM  Johnson & Johnson Earnings Analysis: Q4, 2015 By the Numbers
10:50AM  Commentary: Giddy Up - Its Earnings Season!
10:34AM  J&J Earnings Beat Fails to Cheer Healthcare ETFs
07:02AM  Johnson & Johnson's Newest Billion-Dollar Blockbuster at Motley Fool
12:17AM  CCI approval_Johnson & Johnson at noodls
Jan-27-16 07:38PM  Investor pressures J&J to consider split up: sources
07:37PM  The Perfect Way To Time The Market at Forbes
07:34PM  Investor pressures J&J to consider split up -sources
07:01PM  Cramer: The Fed Interest Rate Hike Hurts the American Worker
06:08PM  RTP robotic surgery developer TransEnterix's stock up as Johnson & Johnson talks potential acquisitions at
04:30PM  Will AbbVie (ABBV) Keep the Earnings Streak Alive in Q4?
03:00PM  The Health Care Delusion Hillary And Trump Share at Forbes
01:41PM  Why TransEnterix Shares Sky-Rocketed 33% Today at Motley Fool
01:24PM  [$$] J&J investors urge activists to press for shake-up at Financial Times
01:02PM  3 Healthcare Stocks You Don't Have to Babysit at Motley Fool
10:59AM  JNJ vs. PNG: Which is the Better Bet Right Now? at Investopedia
10:10AM  Stock Market News for January 27, 2016
10:02AM  3 Key Numbers to Monitor When Amgen Reports Fourth-Quarter Results at Motley Fool
09:35AM  How Did Michael Castors Picks Play Out in Q4? at Insider Monkey
08:02AM  Johnson & Johnson breached its 50 day moving average in a Bullish Manner : January 27, 2016
12:36AM  [$$] Health-Care M&A: Deal Johnson & Johnson In -- Overheard at The Wall Street Journal
12:36AM  [$$] J&Js Revenue Falls on Currency Woes at The Wall Street Journal
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fasolo PeterVP, Global Human ResourcesFeb 03Option Exercise72.54144,56810,486,963182,303Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Sale104.12144,56815,052,42037,735Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Option Exercise72.546,817494,50544,552Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Sale104.096,817709,58837,735Feb 04 06:04 PM
Caruso Dominic JVP, Finance; CFOJan 15Option Exercise0.0011,6020100,336Jan 20 07:25 PM
Fasolo PeterVP, Global Human ResourcesJan 15Option Exercise0.007,511040,578Jan 20 07:25 PM
Gorsky AlexChairman, CEOJan 15Option Exercise0.0027,1730140,534Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanJan 15Option Exercise0.003,053031,616Jan 20 07:25 PM
Ullmann Michael HVP, General CounselJan 15Option Exercise0.006,679083,907Jan 20 07:25 PM
Kapusta Ronald AController, CAOJan 15Option Exercise0.003,896024,699Jan 20 07:25 PM
Stoffels PaulusChief Scientific OfficerJan 15Option Exercise0.0011,2970106,585Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,688040,730Dec 21 05:09 PM
Ullmann Michael HVP, General CounselNov 20Option Exercise58.3422,6261,320,00194,878Nov 24 01:00 PM
Ullmann Michael HVP, General CounselNov 20Sale102.4717,6501,808,54377,228Nov 24 01:00 PM
Caruso Dominic JVP, Finance; CFONov 02Option Exercise58.3420,5691,199,995109,303Nov 04 05:05 PM
Caruso Dominic JVP, Finance; CFONov 02Sale102.2120,5692,102,42388,734Nov 04 05:05 PM
Kapusta Ronald AController, CAOOct 23Option Exercise58.346,239363,98327,042Oct 27 03:38 PM
Kapusta Ronald AController, CAOOct 23Sale99.686,239621,90420,803Oct 27 03:38 PM
PRINCE CHARLESDirectorAug 06Buy99.252,500248,13225,645Aug 10 12:49 PM
PRINCE CHARLESDirectorJun 02Buy99.222,500248,05023,145Jun 03 05:20 PM
Stoffels PaulusChief Scientific OfficerApr 28Option Exercise64.43228,68314,733,404281,723Apr 30 04:56 PM
Stoffels PaulusChief Scientific OfficerApr 28Sale100.73187,25018,862,14294,473Apr 30 04:56 PM
Fasolo PeterVP, Global Human ResourcesMar 05Option Exercise65.37115,3077,537,619147,895Mar 09 05:14 PM
Fasolo PeterVP, Global Human ResourcesMar 05Sale102.40115,30711,807,86332,588Mar 09 05:14 PM
Stoffels PaulusChief Scientific OfficerFeb 09Option Exercise0.0029,073064,647Feb 11 08:16 PM
Caruso Dominic JVP, Finance; CFOFeb 09Option Exercise0.0031,5370101,324Feb 11 08:16 PM
Fasolo PeterVP, Global Human ResourcesFeb 09Option Exercise0.0020,935042,109Feb 11 08:16 PM
Gorsky AlexChairman, CEOFeb 09Option Exercise0.0042,1120130,173Feb 11 08:17 PM